Soliton, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher C. Capelli
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5304 Ashbrook Dr Houston TX United States of America 77081
- IPO Date
- Feb 19, 2019
- CIK
- 0001548187
- Website
- soliton.com
- Similar Companies
- Business
- Soliton, Inc. develops and commercializes medical devices utilizing its proprietary Rapid Acoustic Pulse (RAP) technology platform, which employs designed acoustic shockwaves to treat aesthetic conditions including tattoo removal, cellulite reduction, fibrotic scar treatment, and other indications. The company offers the RESONIC device, FDA-cleared for non-invasive improvement of cellulite appearance and as an adjunct to Q-switched lasers for accelerating tattoo ink clearance by disrupting pigment in macrophages and dermal structures; it also explores applications in skin laxity and liver fibrosis. Founded in 2012 and headquartered in Houston, Texas, Soliton primarily serves dermatologists, plastic surgeons, and aesthetic practitioners in the United States through a select network of providers. In December 2021, Allergan Aesthetics, an AbbVie Inc. subsidiary, completed its acquisition of Soliton for approximately $550 million, integrating RESONIC into its body contouring portfolio alongside products like CoolSculpting Elite to expand non-invasive treatment options.
Allergan Aesthetics Completes Acquisition of Soliton
Why Soliton Popped While the Market Slid Today
Wall Street Breakfast (Podcast)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
Soliton (SOLY) is in Overbought Territory: What's Next?
SOLITON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Soliton, Inc. - SOLY
Soliton Reports First Quarter 2021 Results
Shareholder Alert: Ademi LLP investigates whether Soliton, Inc. has obtained a Fair Price in its transaction with AbbVie
SHAREHOLDER ALERT: WeissLaw LLP Investigates Soliton, Inc.
Soliton Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Soliton, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SOLY
SOLY Stock: Over 20% Increase Intraday Explanation
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
Introducing RESONIC™
Soliton to Report First Quarter 2021 Financial Results on May 13, 2021
Soliton Receives FDA Clearance of Special 510(k)
Soliton Announces Oral Presentation at American Society for Laser Medicine and Surgery Virtual Annual Conference
Soliton Provides Special 510(k) and Commercialization Update
Soliton to Participate in Three Upcoming Healthcare Conferences
Soliton, Inc. (SOLY) CEO Brad Hauser on Q4 2020 Results - Earnings Call Transcript
Soliton to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021